Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A small stake only. This is a long term investment which will pay off. Nube.
Baker Brothers Advisors LP discloses 9.60% ownership in AMRN / Amarin Corp. Plc
February 14, 2020 - Baker Brothers Advisors LP has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 34,620,057 shares of Amarin Corp. Plc (NASDAQ:AMRN). This represents 9.6 percent ownership of the company. In their previous filing dated February 13, 2019, Baker Brothers Advisors LP had reported owning 42,592,824 shares, indicating a decrease of -18.72 percent.
So you calling the Baker Brothers bag holders?
Your attitude explains why you are not wealthy.
We have been saying this for well over 10 years now about Amarin! Did you by any chance sell Netflix several years ago?
Well I think all credibility with these guys is completely lost!
The price may decline slightly with ongoing conditions in the market. But I have cash waiting to be spent. AMRN market is huge and once past the legal bullsh!t. The price should be fine.
P.S. very happy they pull a rabbit out of their hat, making profit was a punch in Oppenheimer.s analysts eye, not to mention others.
Any new LDL-C lowering drugs are DOA!
Good new regarding Cigna, even though they required a PA starting January 2020. Copay for Vascepa dropped in VI/PR region to $65.00 from $100 last December. I don't believe the PA will cause many issues at all.
I was just glad I got rid of them easily. I thought I had a brain tumor My grandfather had died from one. he's the only one who died in his 60's the rest late 70's and 80's my mom and her sisters are still kicking.
P.S. The Cigna PA on Vascepa was no problem, the doctors office took care of it quickly. Before I was off label because of the previous FDA Label. It took an extra week when I discovered they used my insurer on file which was UHC, but corrected that over the phone with the Cigna group/ID number.
Absolutely I had migraines when I moved down to Florida many years ago. Doc prescribed muscle relaxers an Antihistamines, the antihistamines did the trick. Turns out allergies can come back with a vengeance when you relocated. I never had migraines previous to the move.
Not true at all!
A simple answer to your question is no! But you could read the patent!
J.L. Reading many of your post about your life over the years. The care you have given to war veterans and patients in the U.S., you deserve a parking lot full have new and expensive cars. Period!
Might be tough since Amarin holds Patent USB188146B@ Highly purified ethyl EPA and other EPA derivatives. They may have a tough time with manufacturing it.
Inventor
Malcolm Peet
Krishna S. Vaddadi
Current Assignee
Cppib Credit Europe Sa Rl
Amarin Neuroscience Ltd
Amarin Pharmaceuticals Ireland Ltd
True!
You would think it would be based on AA\EPA ratios or EPA blood serum levels. I'm am quite sure there are people in need of EPA who have normal Trig levels. That that's another story!
My 4 year old too I switched from Tylenol to Motrin to help keep fever down. Seems to be effecting more children then adults. Here high fever stopped yesterday. Whew feel better now!
My AMRN down but my NNVC flying high! 16.20 USD +4.20 (35.00%)
Way up from 3.15 where it was 2 weeks ago!
I believe focusing on lipid levels is incidental. EPA action is more complicated then just another Triglyceride lowering agent. Even Reduce-It results show the CVD risk was reduced no matter what the Triglyceride level was.
Example - LDL-C levels are not the best predictor of CVD risk!
Yea well CETP Inhibitors failed CVOTS - yet raised LDL-C around ~100% and Reduce LDL-C ~ 30-40%
The Japanese have been on top of EPA research, way before U.S. medicine. Jelis Trial and many more. The FDA ignored the Jelis trial during the ADCOM for the Marine indication. Not to mention most of the ADCOM panelist's
J.L.
From page 87:
Reducing Residual Cardiovascular Risk.—Cardiovascular events account for one of every three deaths in the United States; about
2,300 Americans die of cardiovascular disease each day. Cholesterol therapies, such as statins, have been successful in reducing risk of cardiovascular disease, but substantial residual and untreated risk remains for these individuals beyond cholesterol management.
A clinical trial called REDUCE-IT has demonstrated a 25 percent relative risk reduction in major adverse cardiovascular events beyond cholesterol management, from the use of highly purified and stable eicosapentaenoic acid (EPA) in addition to statin therapy.
The Committee is concerned that, despite these statistics, many individuals do not regularly access treatments for residual risk beyond statin therapy. The Committee urges NHLBI to support research in this area as well as efforts, particularly through the ‘‘Know Your Numbers’’ campaign, to promote awareness among physicians and patients of the residual cardiovascular risks beyond statin therapy and the importance of taking preventative action to reduce this risk.
Yes thanks for bring this up. I started to take my BP medication at night years ago. My reasoning was, because I read most heart attacks occur in the very early morning period.
Not sure if this is accurate. But any feed backup when the majority of attacks occur would be nice. If you have the statistics available.
Well he's right! Little chance this company will be acquired!
Not even close, try EPA blood serum levels.
The thing is at the top of the page it also show's Vascepa having
preferred brand as of January 1, 2020. Tier 3.
I logged in seems this may be accurate.
Maybe the BAR is much lower for PA. Keep you posted not happy!
Vascepa CAP 1GM
Brand
90-day supply
Total Cost: $917.49
Plan Pays: $722.49
You Pay:
$195.00
View messages
CENTRAL RX
(340) 774-4033
7 Charlotte Amalie St Thomas, VI 00801
Vascepa CAP 1GM
Brand
90-day supply
Total Cost: --
Plan Pays: --
You Pay:
--
Hide messages
This medication needs prior authorization (approval) from Cigna before it’s covered by your plan. Ask your doctor to contact Cigna to request approval.
The pharmacy you've selected is not approved to fill 90-day prescriptions. Please try a new search to find a 90-day pharmacy in your network.
Cigna Formulary 2020 EA-MAPD and I have no PA for my employers plan
VASCEPA CAPS 1GM 3 QL(120/30)
VASCEPA CAPS 0.5GM 3 QL(240/30)
Cigna update As of 01/01/2020
Start date of change*,**
Drug class
Medications moving to preferred brand
January 1, 2020
ASTHMA/COPD/RESPIRATORY
albuterol HFA
CHOLESTEROL MEDICATIONS
Vascepa
DIABETES
Segluromet
Steglatro
INFERTILITY
Gonal-F1, Gonal-F RFF1
SEIZURE DISORDERS
Fycompa
932523 UPDATED_09/25/2019
Changes are being made to Cigna’s Prescription Drug List (formulary) that may affect some of your patients.
These changes are listed by formulary name and by effective date.
Below is the list of medications that are changing coverage levels. Please note that the coverage status of medications under our Prescription Drug Lists are always subject to the cost-share requirements, exclusions and coverage limitations of particular benefit plans.
Drug lists used by patients who have coverage through their employer
STANDARD FORMULARY
PRESCRIPTION DRUG
LIST CHANGES
For Providers 2020
Start date of change*,**
Drug class
Medications becoming
Not true!
I think the Japanese deserve some credit here also! They are miles ahead of the Ivy League Researchers in the U.S.
Amarin gets full credit for recognising the possible therapeutic benefits of EPA and for running the studies and trials that prove its efficacy..TOS does not allow me to tell you what I really think of your comments..
Yep with some 30,000 $20 call options on the line.
Can't imagine a doctor following this routine. Total nonsense posed by the defendants.
Cigna Effective 01/01/2020
Expect UHC update soon! Latest July 1 2020.
Hope the laggards catch up and make changes to their Formulary before end of year!
I looking into others and see if changes are being made before EOY. regarding Vascepa status.
Cigna National Vascepa Preferred Drug as of January 1 2020. Family Plans and Commercial.
To help make sure you have access to coverage for safe, clinically effective and low-cost medications, we regularly review and update the Cigna Prescription Drug List. You can see a list of these changes below. They are listed by drug list name, the date the change starts and by the type of change that’s taking place. Medications are listed alphabetically by drug class.
If you’re taking a medication that’s changing coverage, call your doctor’s office to talk about your options.
Only you and your doctor can decide what’s best for your Treatment.
If you have Cigna pharmacy benefits, you can also log in to the myCigna® app or website to find out how these changes may affect your specific plan.
STANDARD (ALSO KNOWN AS CIGNA NATIONAL) PRESCRIPTION DRUG LIST
Start date of change*,**
Drug class
Medications moving to preferred brand
January 1, 2020
ASTHMA/COPD/RESPIRATORY albuterol HFA
CHOLESTEROL MEDICATIONS Vascepa
DIABETES Segluromet
Steglatro INFERTILITY Gonal-F1, Gonal-F RFF1
SEIZURE DISORDERS Fycompa
It's right in the medical system, when you submit prescription to the pharmacy for a patient, he or she will see Vascepa 1/.5 GM dosage! Doc, Probably need to go out and buy a system that will connect to the WWW. Some Docs out there still write scripts by hand and look up drugs in the reference book.
Maybe quite a few out of touch with the AHA. Busy scheduling! It is their job to keep up to date with new Cardiovascular drugs and trials. Information provided by the AHA.
Not if it's an off label - Trig's Lower than 500. Hopefully this limit has been lowered to the 150 limit or even less. I had BC/BS for years. Then we switch to UHC this turned into a problem since they had vascpea with a PA for Trig Levels.
The trig level should be removed since Reduce-IT label sNDA was approved.
Yes there are many formulary's with variences. I chose a couple of Cigna comprehensive formularies. HMO Insurer and one from Texas, these can vary from state to state. Same goes for BC/BS variances in copay but I don't remember seeing any PA for these either. I only ran into a problem with UHC which was had a PA for vascepa. Glad we dumped UHA. I think but the end of the year all the health insurance carriers formulary's will be no PA and cheaper COPAY. The actuaries are always look at a way to reduce claims and Vascepa fits the bill. By reducing hospital stays or even ER visits.
Wow glad you survived - shocks me when I hear Cardiologist have never heard of V. You would think a drug highlighted by the AHA would have gotten a lot of attention and word of mouth. Maybe a bit out of touch.
Cigna was mentioned in the thread by CallMustang. Your right you did not specify your carrier, so which one moved to PA, I don't believe you!
I never said carriers moved to PA - The opposite will happen soon for those who are at PA on Tier 3 or higher.
Actually you are incorrect - Cigna 2020 Formulary has no PA Formulary-EA-MAPD.
VASCEPA CAPS 1GM 3 QL(120/30)
VASCEPA CAPS 0.5GM 3 QL(240/30)
Also I am in Puerto Rico/VI region no PA for Vascepa and $100 Copay!
And looking at a Cigna Texas region formulary 2019 seems no changes have been made since. No PA requirements in 2019.
VASCEPA CAPS 1GM $0(Tier 2) QL (120 per 30 days)
VASCEPA CAPS 0.5GM $0(Tier 2) QL (240 per 30 days)